Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors

1. A process for the production of a compound of formula I

wherein

A stands for an aryl group, a benzyl group or a phenethyl group, optionally substituted by:

one or more radicals of C 1 –C 5 -alkyl, C 1 –C 5 -alkoxy, C 1 –C 5 -alkylthio, C 1 –C 5 -perfluoroalkyl, halogen, hydroxy, cyano, or nitro; or

—O—(CH 2 ) n —O—, —O—(CH 2 ) n —CH 2 —, —O—CH═CH—, or —(CH 2 ) n+2 —, wherein n+1 or 2, and wherein the two terminal atoms in these groups are linked with directly adjacent ring-carbon atoms of the aryl, benzyl or phenethyl group to form a fused ring; or

NR 4 R 5 , wherein R 4 and R 5 , independently of one another, are hydrogen, C 1 –C 5 -alkyl or (CO)—C 1 –C 5 -alkyl,

R 1 and R 2 , independently of one another, are a hydrogen atom, a methyl or an ethyl group or together with the carbon atom of the chain form a C 3 –C 6 -cycloalkyl ring,

R 3 means a C 1 –C 3 -alkyl group or a C 1 –C 3 -alkyl group optionally partially or completely fluorinated,

B means a methylene group or a carbonyl group, wherein the methylene group is optionally substituted by a methyl or an ethyl group, and

Q means a quinolinyl group or an isoquinolinyl group that is linked via any position and that optionally can be substituted by one or more radicals from the group C 1 –C 5 -alkyl, wherein C 1 –C 5 -alkyl is optionally substituted by 1–3 hydroxy groups and/or 1–3 COOR 6 groups; C 1 –C 5 -alkoxy; C 1 –C 5 -alkylthio; C 1 –C 5 -perfluoroalkyl; halogen; hydroxy; a carbonyl-oxygen atom; cyano; nitro; or

NR 4 R 5 , wherein R 4 and R 5 , independently of one another, are hydrogen, C 1 –C 5 -alkyl or (CO)—C 1 –C 5 -alkyl;

COOR 6 , wherein R 6 means hydrogen or a C 1 –C 5 -alkyl group;

(CO)NR 7 R 8 , wherein R 7 and R 8 , independently of one another, mean hydrogen or a C 1 –C 5 -alkyl group;

or a (C 1 –C 5 -alkylene)-O—(CO)—(C 1 –C 5 )alkyl group; wherein, the C 1 –C 5 -alkyl groups in A, and R 4 –R 8 are optionally substituted by 1–3 hydroxy groups and/or 1–3 COOR 6 groups;

wherein when B=CO, comprising either:

A1)

reacting an α-keto acid of formula II

with an amine of formula

Q-NH 2

to form α-ketoamide of formula III,

optionally in the presence of at least one dehydrating coupling reagent or after converting the acid function into an acid chloride, and then reacting either an alkyl metal compound or a silicon compound of formula IV

(R 9 ) 3 —Si—R 3   IV

wherein R 9 means a C 1 –C 5 -alkyl group,

in the presence of a catalyst to form a compound of formula I, or

A2)

optionally esterifying an α-keto acid of formula II

to obtain an α-keto acid of formula V

wherein R 10 means hydrogen or C 1 –C 4 -alkyl,

and then, reacting with an alkyl metal compound or a silicon compound of formula IV to form a compound of formula VI

wherein R 11 means hydrogen or C 1 –C 4 alkyl,

optionally saphonifying the ester, and

then reacting the compound of formula VI with an amine of formula

Q-NH 2

in the presence of an activating reagent, optionally in the presence of a catalyst, to form a compound of formula I,

or

when B means a methylene group that is optionally substituted by a methyl or ethyl group,

B1)

comprising either reacting

a compound of formula VII or VIII

wherein LG stands for any leaving group,

with a compound of formula IX or X

Q-NH—R 12   IX

Q-N═C═O  X

wherein R 12 means a hydrogen atom, a C 1 –C 5 -acyl group of an alkoxy group or an aryloxycarbonyl group,

and cleaving an optionally intermediately formed oxazolidinone to obtain a compound of formula I

or

B2)

reacting a compound of formula VII or VIII with a nitrogen nucleophile and then optionally reducing with a reagent or performing a transition-metal-catalyzed hydrogenolysis to obtain a compound of formula XI

and then optionally reacting a halogenated derivative of quinoline, isoquinoline, partially or completely hydrogenated quinoline, or partially or completely hydrogenated isoquinoline under base catalysis or transition-metal catalysis,

or

B3)

reacting under reductive anamation a compound of formula XII,

and R 13 means hydrogen, methyl or ethyl, with a compound of formula

Q—NH 2

to form a compound of formula I.

2. A process for the production of a compound of formula I

wherein

A stands for an aryl group, a benzyl group or a phenethyl group, optionally substituted by:

one or more radicals of C 1 –C 5 -alkyl, C 1 –C 5 -alkoxy, C 1 –C 5 -alkylthio, C 1 –C 5 -perfluoroalkyl, halogen, hydroxy, cyano, or nitro; or —O—(CH 2 ) n —O—, —O—(CH 2 ) n —CH 2 —, —O—CH═CH—, or —(CH 2 ) 2 —, wherein n=1 or 2, and wherein the two terminal atoms in these groups are linked with directly adjacent ring-carbon atoms of the aryl, benzyl or phenethyl group to form a fused ring; or

NR 4 R 5 , wherein R 4 and R 5 , independently of one another, are hydrogen, C 1 –C 5 -alkyl or (CO)—C 1 –C 5 -alkyl,

R 1 and R 2 , independently of one another, are a hydrogen atom, a methyl or an ethyl group or together with the carbon atom of the chain form a C 3 –C 6 -cycloalkyl ring,

R 3 means a C 1 –C 3 -alkyl group or a C 1 –C 3 -alkyl group optionally partially or completely fluorinated,

B means a methylene group or a carbonyl group, wherein the methylene group is optionally substituted by a methyl or an ethyl group, and

Q means a quinolinyl group, an isoquinolinyl group, a partially or completely hydrogenated quinolinyl group or a partially or completely hydrogenated isoquinolinyl group that is linked via any position and that optionally can be substituted by one or more radicals from the group C 1 –C 5 -alkyl, wherein C 1 –C 5 -alkyl is optionally substituted by 1–3 hydroxy groups and/or 1–3 COOR 6 groups; C 1 –C 5 -alkoxy; C 1 –C 5 -alkylthio; C 1 –C 5 -perfluoroalkyl; halogen; hydroxy; a carbonyl-oxygen atom; cyano; nitro; or

NR 4 R 5 , wherein R 4 and R 5 , independently of one another, are hydrogen, C 1 –C 5 -alkyl or (CO)—C 1 –C 5 -alkyl;

COOR 6 , wherein R 6 means hydrogen or a C 1 –C 5 -alkyl group;

(CO)NR 7 R 8 , wherein R 7 and R 8 , independently of one another, mean hydrogen or a C 1 –C 5 -alkyl group;

or a (C 1 –C 5 -alkylene)-O—(CO)—(C 1 –C 5 )alkyl group; wherein, the C 1 –C 5 -alkyl groups in A, and R 4 –R 8 are optionally substituted by 1–3 hydroxy groups and/or 1–3 COOR 6 groups;

wherein when B=CO,

comprising either:

A1)

reacting an α-keto acid of formula II

with an amine of formula

Q—NH 2

to form α-ketoamide of formula III,

optionally in the presence of at least one dehydrating coupling reagent or after converting the acid function into an acid chloride, and then reacting either an alkyl metal compound or a silicon compound of formula IV

(R 9 ) 3 —Si—R 3   IV

wherein R 9 means a C 1 –C 5 -alkyl group,

in the presence of a catalyst to form a compound of formula I, or

A2)

optionally esterifying an α-keto acid of formula II

to obtain an α-keto acid of formula V

wherein R 10 means hydrogen or C 1 –C 4 -alkyl,

and then, reacting with an alkyl metal compound or a silicon compound of formula IV to form a compound of formula VI

wherein R 11 means hydrogen or C 1 –C 4 alkyl,

optionally saphonifying the ester, and

then reacting the compound of formula VI with an amine of formula

Q—NH 2

in the presence of an activating reagent, optionally in the presence of a catalyst, to form a compound of formula I,

or

when B means a methylene group that is optionally substituted by a methyl or ethyl group,

B1)

comprising either reacting

a compound of formula VII or VIII

wherein LG stands for any leaving group,

with a compound of formula IX or X

Q—NH—R 12   IX

Q—N═C═O  X

wherein R 12 means a hydrogen atom, a C 1 –C 5 -acyl group of an alkoxy group or an aryloxycarbonyl group,

and cleaving an optionally intermediately formed oxazolidinone to obtain a compound of formula I

or

B2)

reacting a compound of formula VII or VIII with a nitrogen nucleophile and then optionally reducing with a reagent or performing a transition-metal-catalyzed hydrogenolysis to obtain a compound of formula XI

and then optionally reacting a halogenated derivative of quinoline, isoquinoline, partially or completely hydrogenated quinoline, or partially or completely hydrogenated isoquinoline under base catalysis or transition-metal catalysis,

or

B3)

reacting under reductive animation a compound of formula XII,

and R 13 means hydrogen, methyl or ethyl,

with a compound of formula

Q—NH 2

Q-N═C═O  X

to form a compound of formula I.

3. A process according to claim 1 , wherein B means a methylene group.

4. A process according to claim 1 , wherein A is an aryl radical.

5. A process according to claim 1 , wherein A is an aryl radical optionally substituted by one or more radicals from the group C 1 –C 5 -alkyl, C 1 –C 5 -alkoxy, C 1 –C 5 -perfluoroalkyl, halogen, hydroxy, or nitro, or —O—(CH 2 ) n —O—, —O—(CH 2 ) n —CH 2 —, —O—CH═CH—, or —(CH 2 ) n+2 —, wherein n=1 or 2, and their terminal atoms in these groups are linked with immediately adjacent ring-carbon atoms.

6. A compound according to claim 1 , wherein R 1 and R 2 together with the carbon atom of the chain mean a C 3 –C 6 -cycloalkyl ring.

7. A process according to claim 1 , wherein Q means an optionally substituted quinolinyl group that is linked via any position.

8. A process according to claim 1 , wherein A is a phenyl radical that is substituted by a hydroxy group, a methoxy group, or a halogen atom.

9. A pharmaceutical composition comprising a compound obtainable by a process according to claim 2 , and a pharmaceutically acceptable vehicle.

10. A method of treating an inflammatory disease, comprising administrating an effective amount of a compound obtainable by a process according to claim 2 to a patient in need thereof.

11. A process according to claim 1 , wherein A is phenyl or naphthyl.

12. A process according to claim 1 , wherein R 1 and R 2 are together a cyclopropyl ring.

13. A process according to claim 1 , wherein the C 1 –C 5 alkoxy group in A and Q is a methoxy or an ethoxy group.

14. A process according to claim 1 , wherein the C 1 –C 5 -alkylthio group in A and Q is a methylthio or an ethylthio group.

15. A process according to claim 1 , wherein Q is a quinoline ring linked at the 4-, 5- or 8-position or an isoquinoline ring linked at the 1-position.

16. A process according to claim 1 , wherein LG is a halide or sulfonate.

17. A process according to claim 1 , wherein B means CO.